Abstract
The DNA binding protein and chromatin structural regulator DEK regulate many cellular processes. These include proliferation, differentiation, apoptosis, senescence, DNA repairing and the maintenance of stem cell phenotype. DEK is increasingly recognized as a crucial player in many steps of cancer initiation and progression, and is precisely regulated by abundant promoting and inhibiting factors directly or indirectly. DEK may serve as an architectural modulating protein to regulate the expression and function of multiple human genes in cancer cells. In this article we have reviewed the specificities and complexities of DEK in the regulation of transcription factors and global chromatin, including its biologic roles in malignant cells, and summarized the current research. The possible use of DEK as a diagnostic marker and drug target in the prevention or treatment of tumors is also discussed.
Keywords: DEK, cancer, gene regulations, biologic roles, diagnostic marker, drug target.
Graphical Abstract
Current Cancer Drug Targets
Title:The Complexity of DEK Signaling in Cancer Progression
Volume: 18 Issue: 3
Author(s): Yong Teng*, Liwei lang and Catherine E. Jauregui
Affiliation:
- Department of Oral Biology, Dental College of Georgia, Augusta University, Augusta, Georgia,United States
Keywords: DEK, cancer, gene regulations, biologic roles, diagnostic marker, drug target.
Abstract: The DNA binding protein and chromatin structural regulator DEK regulate many cellular processes. These include proliferation, differentiation, apoptosis, senescence, DNA repairing and the maintenance of stem cell phenotype. DEK is increasingly recognized as a crucial player in many steps of cancer initiation and progression, and is precisely regulated by abundant promoting and inhibiting factors directly or indirectly. DEK may serve as an architectural modulating protein to regulate the expression and function of multiple human genes in cancer cells. In this article we have reviewed the specificities and complexities of DEK in the regulation of transcription factors and global chromatin, including its biologic roles in malignant cells, and summarized the current research. The possible use of DEK as a diagnostic marker and drug target in the prevention or treatment of tumors is also discussed.
Export Options
About this article
Cite this article as:
Teng Yong*, lang Liwei and Jauregui E. Catherine , The Complexity of DEK Signaling in Cancer Progression, Current Cancer Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1568009617666170522094730
DOI https://dx.doi.org/10.2174/1568009617666170522094730 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
Current Drug Targets Application of Radiolabeled Antibodies in Targeting Therapy of Breast Cancer
Current Molecular Imaging (Discontinued) Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry